A Canadian study has concluded a novel dual-hormone artificial pancreas system improves glucose control in patients with type 1 diabetes.
Researchers from McGill University’s Faculty of Medicine compared the dual-hormone system with a rapid insulin-alone artificial pancreas. According to the findings the dual-hormone artificial pancreas increased the blood glucose time in range from 74% to 84%. The hormones used in the dual system are insulin and pramlintide which is a synthetic form of the hormone amylin. Pramlintide works to reduce post-meal blood glucose levels by inhibiting the action of the glucose-raising hormone glucagon. Pramlintide slowed down food absorption, therefore giving insulin more time to work. Patients using the combination of hormones experienced a significant improvement in the time spent within the target blood glucose range.